Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2023 Sep 18;30(9):8563-8574.
doi: 10.3390/curroncol30090621.

Capecitabine/Mitomycin versus 5-Fluorouracil/Mitomycin in Combination with Simultaneous Integrated Boost Intensity-Modulated Radiation Therapy for Anal Cancer

Laurent Mineur  1 , Léa Vazquez  1 , Mohamed Belkacemi  2 , Clémence Toullec  1 , Newfel Bentaleb  1 , Rania Boustany  1 , Frederi Plat  1
Affiliations

Capecitabine/Mitomycin versus 5-Fluorouracil/Mitomycin in Combination with Simultaneous Integrated Boost Intensity-Modulated Radiation Therapy for Anal Cancer

Laurent Mineur et al. Curr Oncol. .

Abstract

Since EXTRA, a non-randomized phase II trial with 31 patients, explored the use of capecitabine, mitomycin and radiation therapy (RT) in the treatment of localized squamous cell carcinoma of the anal canal (SCCAC), this treatment has been considered as an acceptable alternative to infusional 5-FU. However, the differences in efficacy between capecitabine and 5-FU in chemoradiation therapy (CRT) with simultaneous integrated boost (SIB) radiation therapy (SIB-IMRT) for local SCCAC are not well documented. Patients included in this prospective monocentric cohort study were treated with SIB-RapidArc (a unique RT method treatment for all patients: identical technique, volume and constraints for at-risk organs), mitomycin C and 5-FU each day of RT for 7 weeks (group 1) or capecitabine each day of RT (group 2). Patients treated between July 2009 and August 2017 (group 1) and between November 2012 and April 2018 (group 2) for local SCCAC T2-4 classified as N, M0 or T, N1-3, M0 were included. Primary endpoints were progression-free survival (PFS) and acute toxicities. Results: One hundred forty-seven patients were included, 91 in group 1 and 56 in group 2. The two groups were statistically comparable in terms of sex, Eastern Cooperative Oncology Group Performance Status (ECOG PS) and TNM. With a median duration of follow-up of 53.5 months, the PFS rate at 3 years was 80% for group 1 and 75% for group 2 (p = 0.32). The 3-year colostomy-free survival rate was 92% for group 1 and 85% for group 2 (p = 0.11). The rate of patients with at least one grade 3 or higher acute toxicity was 35.5% in group 1 and 21.4% in group 2 (p = 0.10), with a trend of fewer acute toxicities with capecitabine. Conclusion: Capecitabine/mitomycin in combination with SIB RapidArc radiation therapy for anal cancer seems as effective as 5-FU-based chemotherapy and is well tolerated with minimal toxicity.

Keywords: 5-FU; anal cancer; capecitabin; radiation therapy; toxicity.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

Figures

Figure 1
Figure 1
Kaplan–Meier curves of progression-free survival for 5-FU-treated patients (group 1) versus capecitabine-treated (group 2) patients.
Figure 2
Figure 2
Kaplan–Meier curves of colostomy-free survival for 5-FU-treated patients (group 1) versus capecitabine-treated (group 2) patients.
Figure 3
Figure 3
Kaplan–Meier curves of overall survival for 5-FU-treated patients (group 1) versus capecitabine-treated (group 2) patients.
See this image and copyright information in PMC

References

    1. De Martel C., Ferlay J., Franceschi S., Vignat J., Bray F., Forman D., Plummer M. Global burden of cancers attributable to infections in 2008: A review and synthetic analysis. Lancet Oncol. 2012;13:607–615. doi: 10.1016/S1470-2045(12)70137-7. - DOI - PubMed
    1. Valvo F., Ciurlia E., Avuzzi B., Doci R., Ducreux M., Roelofsen F., Roth A., Trama A., Wittekind C., Bosset J.-F. Cancer of the anal region. Crit. Rev. Oncol. Hematol. 2019;135:115–127. doi: 10.1016/j.critrevonc.2018.12.007. - DOI - PubMed
    1. Bouvier A.M., Belot A., Manfredi S., Jooste V., Uhry Z., Faivre J., Duport N., Grabar S., French Network of Cancer Registries FRANCIM Trends of incidence and survival in squamous-cell carcinoma of the anal canal in France: A population-based study. Eur. J. Cancer. Prev. 2016;25:182–187. doi: 10.1097/CEJ.0000000000000163. - DOI - PubMed
    1. Nigro N.D., Seydel H.G., Considine B., Vaitkevicius V.K., Leichman L., Kinzie J.J. Combined preoperative radiation and chemotherapy for squamous cell carcinoma of the anal canal. Cancer. 1983;51:1826–1829. doi: 10.1002/1097-0142(19830515)51:10<1826::AID-CNCR2820511012>3.0.CO;2-L. - DOI - PubMed
    1. UKCCCR Anal Cancer Trial Working Party Epidermoid anal cancer: Results from the UKCCCR randomised trial of radiotherapy alone versus radiotherapy, 5-fluorouracil, and mitomycin. Lancet. 1996;348:1049–1054. doi: 10.1016/S0140-6736(96)03409-5. - DOI - PubMed

Supplementary concepts